Organon & Co.
OGN · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | 0.07 | -0.58 | -0.13 |
| FCF Yield | 5.37% | 7.19% | -0.57% | 6.71% |
| EV / EBITDA | 23.77 | 24.08 | 37.69 | 35.79 |
| Quality | ||||
| ROIC | 2.16% | 1.91% | 2.65% | 2.39% |
| Gross Margin | 53.50% | 54.83% | 55.58% | 56.28% |
| Cash Conversion Ratio | 1.65 | 1.52 | 0.86 | 3.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.81% | 0.61% | 0.80% | 1.22% |
| Free Cash Flow Growth | -17.68% | 922.73% | -108.53% | 296.92% |
| Safety | ||||
| Net Debt / EBITDA | 17.73 | 18.48 | 25.87 | 24.52 |
| Interest Coverage | 2.80 | 2.47 | 2.62 | 2.24 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.50 | 0.49 | 0.53 |
| Cash Conversion Cycle | 133.38 | 133.69 | 134.94 | 106.01 |